Delcath Systems, Inc. Announces Inclusion of CHEMOSAT Hepatic Delivery System for Melphalan as a Recommended Liver-Directed Regional Therapy Option in the ESMO–EURACAN Clinical Practice Guidelines f
Go back to Delcath Systems, Inc. Announces Inclusion of CHEMOSAT Hepatic Delivery System for Melphalan as a Recommended Liver-Directed Regional Therapy Option in the ESMO–EURACAN Clinical Practice Guidelines f| DELCATH SYSTEMS (NASDAQ: DCTH) | Delayed: 12.59 -0.36 (2.78%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $12.95 | 52 Week High | $4.72 | |||
| Open | $12.91 | 52 Week Low | $0.22 | |||
| Day High | $12.92 | P/E | N/A | |||
| Day Low | $12.47 | EPS | $-102.40 | |||
| Volume | 444,031 | |||||
